In the absence of disease-modifying therapy, a small-molecule activator of TFEB is therefore expected to have therapeutic potential for the treatment of AD, other tauopathies, as well as several other neurological disorders characterized by the accumulation of protein aggregates. Here, TFEB is linked to tauopathy.